Rogne Bioscience will present Topical Biologic for psoriasis at SID meeting

[Fred]

Here's a new one for people with Psoriasis, Rogne Bioscience are developing a Topical Biologic for the treatment of psoriasis and will present data at the Society of Investigative Dermatology (SID) Annual Meeting being held May 6-9, 2015 at the Hilton Atlanta, in Atlanta, Georgia.

Quote:

---

Rogne Bioscience, a privately-held biotechnology company developing a topical biologic for psoriasis, today announced that preclinical and mechanism of action data will be presented during a poster session at the Society of Investigative Dermatology (SID) Annual Meeting being held May 6-9, 2015 at the Hilton Atlanta, in Atlanta, Georgia.

Rogne is advancing the development of RON2315, a novel, low MW (<1700 daltons) peptide as a topical treatment for psoriasis. The peptide demonstrates highly potent anti-inflammatory activity in vitro, and when applied topically to an IL-23 dependent model of dermal inflammation, RON2315 inhibits inflammation in a dose-dependent manner. Cellular and biochemical studies in human dendritic cells show that RON2315 acts by regulating the activity of NFKB-p65, thereby inhibiting the secretion of IL-23. Dendritic cells have been shown to be the primary dermal source of IL-23 driving the psoriatic disease process.

"These data highlight a novel anti-inflammatory mechanism that we believe will be a safe, topical treatment with biologic efficacy for hyper-immune diseases such as psoriasis," said Karl Beutner, CMO. "With the demonstration that we can easily deliver the peptide into the skin and the completion of our safety/toxicology studies, our development program is progressing rapidly. We expect to have clinical proof-of-concept data in Q3 of 2015," said Lena Wu, Ph.D. CEO.

The schedule for Rogne's poster presentation is as follows:

Presentation Title: RON2315: A novel human biologic for the topical treatment of psoriasis
Location: Galleria Exhibit Hall
Poster number: 001
Date and Time: Poster Session I, Thursday, May 7, 2015, 10:00 am – 12:00 pm

Source: prnewswire.com

[jiml]

That's a good new one some one thinking along different lines, it will be popular with patients as many dread the thought of injections or tablets, it will certainly be interesting to follow any trials to see how well it works, it's got to be less harmful than topical steroids I would think

[Quest4Cure]

This is another pathway IL-23....to the immune system ....shut it down....anti bodies attacking itselfcausing build up of skin before it can be shed naturally. Topical Treatment sI like very much....